InterMune Email Format

Biotechnology ResearchCalifornia, United States51-200 Employees

InterMune is a mid-sized biotechnology company based in South San Francisco, California, focused on research, development and commercialization of therapies for pulmonology and orphan fibrotic diseases. Its work aims to deliver new treatment options for patients and families worldwide, guided by core values such as integrity, accountability, creativity and teamwork. A primary focus is idiopathic pulmonary fibrosis, a progressive and ultimately fatal lung disease, where the company pursues innovative therapeutic approaches. Esbriet, the brand name for pirfenidone, is approved for IPF in the European Union and Canada, and InterMune has pursued U.S. regulatory registration for it through a Phase 3 program.

In 2014, Roche acquired InterMune, after which its IPF therapy Esbriet became part of Roche's portfolio.

Sign up for free to view info

Company overview Employee directory